398 related articles for article (PubMed ID: 17665444)
21. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
[TBL] [Abstract][Full Text] [Related]
22. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma.
Cuzzocrea S; Mazzon E; Dugo L; Patel NS; Serraino I; Di Paola R; Genovese T; Britti D; De Maio M; Caputi AP; Thiemermann C
Arthritis Rheum; 2003 Dec; 48(12):3544-56. PubMed ID: 14674008
[TBL] [Abstract][Full Text] [Related]
23. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
[TBL] [Abstract][Full Text] [Related]
24. Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice.
Treschow AP; Teige I; Nandakumar KS; Holmdahl R; Issazadeh-Navikas S
Arthritis Rheum; 2005 Dec; 52(12):3739-48. PubMed ID: 16320324
[TBL] [Abstract][Full Text] [Related]
25. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis.
Colucci S; Brunetti G; Cantatore FP; Oranger A; Mori G; Quarta L; Cirulli N; Mancini L; Corrado A; Grassi FR; Grano M
J Pathol; 2007 May; 212(1):47-55. PubMed ID: 17370327
[TBL] [Abstract][Full Text] [Related]
26. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U
Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601
[TBL] [Abstract][Full Text] [Related]
27. Complete Freund's adjuvant suppresses the development and progression of pristane-induced arthritis in rats.
Zheng CL; Hossain MA; Kukita A; Ohki K; Satoh T; Kohashi O
Clin Immunol; 2002 May; 103(2):204-9. PubMed ID: 12027426
[TBL] [Abstract][Full Text] [Related]
28. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
29. [Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis--new therapeutical opportunities].
Kmieć Z; Sokołowska I
Pol Merkur Lekarski; 2007 Apr; 22(130):300-4. PubMed ID: 17684931
[TBL] [Abstract][Full Text] [Related]
30. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
[TBL] [Abstract][Full Text] [Related]
31. THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis.
Tomita T; Kakiuchi Y; Tsao PS
Arthritis Res Ther; 2006; 8(1):R7. PubMed ID: 16356194
[TBL] [Abstract][Full Text] [Related]
32. RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways.
Nakao A; Fukushima H; Kajiya H; Ozeki S; Okabe K
Biochem Biophys Res Commun; 2007 Jun; 357(4):945-50. PubMed ID: 17467668
[TBL] [Abstract][Full Text] [Related]
33. Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis.
Kwak HB; Ha H; Kim HN; Lee JH; Kim HS; Lee S; Kim HM; Kim JY; Kim HH; Song YW; Lee ZH
Arthritis Rheum; 2008 May; 58(5):1332-42. PubMed ID: 18438854
[TBL] [Abstract][Full Text] [Related]
34. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
[TBL] [Abstract][Full Text] [Related]
36. Effects of an antagonist of the bombesin/gastrin-releasing peptide receptor on complete Freund's adjuvant-induced arthritis in rats.
Oliveira PG; Brenol CV; Edelweiss MI; Brenol JC; Petronilho F; Roesler R; Dal-Pizzol F; Schwartsmann G; Xavier RM
Peptides; 2008 Oct; 29(10):1726-31. PubMed ID: 18590783
[TBL] [Abstract][Full Text] [Related]
37. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells.
Grevers LC; de Vries TJ; Everts V; Verbeek JS; van den Berg WB; van Lent PL
Ann Rheum Dis; 2013 Feb; 72(2):278-85. PubMed ID: 22918932
[TBL] [Abstract][Full Text] [Related]
38. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis.
Saito H; Kojima T; Takahashi M; Horne WC; Baron R; Amagasa T; Ohya K; Aoki K
Arthritis Rheum; 2007 Apr; 56(4):1164-74. PubMed ID: 17393436
[TBL] [Abstract][Full Text] [Related]
39. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha.
Edwards CK; Bendele AM; Reznikov LI; Fantuzzi G; Chlipala ES; Li L; Moldawer LL; Mountz JD; Li YY; Dinarello CA
Arthritis Rheum; 2006 Sep; 54(9):2872-85. PubMed ID: 16947419
[TBL] [Abstract][Full Text] [Related]
40. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation.
Keeble J; Russell F; Curtis B; Starr A; Pinter E; Brain SD
Arthritis Rheum; 2005 Oct; 52(10):3248-56. PubMed ID: 16200599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
